Venous thromboembolism following major orthopedic surgery: Review of epidemiology and economics

American Journal of Health-System Pharmacy

Volumn 58, Issue SUPPL. 2, 2001, Pages

  Edelsberg, J ^a   Ollendorf, D ^a   Oster, G ^a  

^a POLICY ANALYSIS INC PAI   (United States)

Author keywords

Anticoagulants; Arthroplasty; Costs; Epidemiology; Hip fractures; Pharmacoeconomics; Surgery; Thromboembolism; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DALTEPARIN; DEXTRAN; DIPYRIDAMOLE; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG COST; HIP ARTHROPLASTY; HIP FRACTURE; HUMAN; KNEE ARTHROPLASTY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; THROMBOEMBOLISM;

EID: 0034753179     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.suppl_2.s4     Document Type: Conference Paper

References (54)

1. Prevention of venous thromboembolism
2. The incidence of venous thromboembolism after total hip arthroplasty. A specific hypotensive epidural anesthesia protocol
3. Venous thromboembolic disease after hip surgery. Risk factors, prophylaxis, and diagnosis
4. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: The ECAT DVT Study. European Concerted Action on Thrombosis
5. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery
6. Female gender and resistance to activated protein C (FV:QS06) as potential risk factors for thrombosis after elective hip arthroplasty
7. Venous thromboembolism prophylaxis after total hip or knee arthroplasty: A survey of Canadian orthopedic surgeons
8. Survey of use of thromboprophylaxis for routine total hip replacement by British orthopaedic surgeons
9. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial
10. Differences in mortality after fracture of hip: The East Anglian audit
11. Lower-extremity venous thrombosis in patients with acute hip fractures: Determination of anatomic location and time of onset with compression sonography
12. The preoperative prevalence and postoperative incidence of thromboembolism in patients with hip fractures treated with dextran prophylaxis
13. Treatment and survival among elderly Americans with hip fractures: A population-based study
14. Mortality after total knee arthroplasty in patients with osteoarthrosis and rheumatoid arthritis
15. Mortality after total hip replacement: 0-10-Year follow-up of 3,543 patients in the Norwegian Arthroplasty Register
16. Postthrombotic syndrome after hip or knee arthroplasty: A cross-sectional study
17. Clinical course and incidence of postthrombophlebitic syndrome after profound asymptomatic deep vein thrombosis. Results of a transverse epidemiologic study
18. Antithrombotic agents and thromboembolic disease
19. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty
20. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. A meta-analysis of randomized trials
21. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin
22. Significance of deep venous thrombosis in the lower extremity after total joint arthroplasty
23. Prolonged thromboprophylaxis following hip replacement surgery - Results of a double blind, prospective, randomized, placebo-controlled study with dalteparin (Fragmin)
24. Deep-vein thrombosis following total knee replacement. An analysis of six hundred and thirty-eight arthroplasties
25. Thromboembolism following hip fracture
26. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement
27. "Delayed" prophylactic anticoagulation: A study of results and complications in 2,012 total hip arthroplasties
28. Venous thromboembolism associated with hip and knee arthroplasty: Current prophylactic practices and outcomes
29. The incidence of fatal pulmonary embolism after knee replacement with no prophylactic anticoagulation
30. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis
31. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge
32. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: The post-arthroplasty screening study. A randomized, controlled trial
33. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: A multi-institutional cohort study of patients who underwent hip or knee arthroplasty
34. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: A randomized, double-blind, placebo-controlled trial
35. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty
36. Autopsy-verified major pulmonary embolism after hip fracture
37. Pulmonary embolism and mortality in patients with fractured hips -A prospective consecutive series
38. Late occurring clinical deep vein thrombosis in joint-operated patients
39. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery
40. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement
41. Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism
42. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis
43. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomized trial
44. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis
45. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis
46. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis
47. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis
48. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis
49. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
50. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin
51. Recurrent venous thromboembolism after deep vein thrombosis: Incidence and risk factors
52. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis
53. Postphlebitic syndrome after hip arthroplasty. 43 Patients followed at least 5 years
54. Medical costs of treating venous stasis ulcers: Evidence from a retrospective cohort study